Roche Holding AG

SWX:ROG Stock Report

Market Cap: CHF 209.1b

Roche Holding Valuation

Is ROG undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

5/6

Valuation Score 5/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of ROG when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: ROG (CHF258.7) is trading below our estimate of fair value (CHF692.62)

Significantly Below Fair Value: ROG is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for ROG?

Other financial metrics that can be useful for relative valuation.

ROG key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue3.9x
Enterprise Value/EBITDA11.2x
PEG Ratio2.2x

Price to Earnings Ratio vs Peers

How does ROG's PE Ratio compare to its peers?

The above table shows the PE ratio for ROG vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average40.9x
NOVN Novartis
24.8x10.2%CHF 202.2b
DESN Dottikon ES Holding
43.5xn/aCHF 3.5b
LONN Lonza Group
57x20.6%CHF 37.3b
AZN AstraZeneca
38.4x15.7%UK£187.6b
ROG Roche Holding
17.9x8.3%CHF 209.1b

Price-To-Earnings vs Peers: ROG is good value based on its Price-To-Earnings Ratio (17.9x) compared to the peer average (40.9x).

Price to Earnings Ratio vs Industry

How does ROG's PE Ratio compare vs other companies in the European Pharmaceuticals Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a11.3%
 n/an/an/a
No. of CompaniesPE048121620

Fetching data

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a11.3%
 n/an/an/a
No more companies

Price-To-Earnings vs Industry: ROG is good value based on its Price-To-Earnings Ratio (17.9x) compared to the European Pharmaceuticals industry average (25.5x).

Price to Earnings Ratio vs Fair Ratio

What is ROG's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

ROG PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio17.9x
Fair PE Ratio36.1x

Price-To-Earnings vs Fair Ratio: ROG is good value based on its Price-To-Earnings Ratio (17.9x) compared to the estimated Fair Price-To-Earnings Ratio (36.1x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst ROG forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentCHF 258.70
CHF 274.00
+5.9%
19.8%CHF 432.00CHF 210.00n/a19
Jul ’25CHF 250.10
CHF 278.58
+11.4%
20.4%CHF 428.00CHF 210.00n/a19
Jun ’25CHF 231.00
CHF 277.53
+20.1%
20.5%CHF 428.00CHF 210.00n/a19
May ’25CHF 220.60
CHF 279.83
+26.9%
20.6%CHF 428.00CHF 210.00n/a18
Apr ’25CHF 229.70
CHF 281.28
+22.5%
19.9%CHF 424.00CHF 210.00n/a18
Mar ’25CHF 233.20
CHF 282.94
+21.3%
19.3%CHF 424.00CHF 210.00n/a18
Feb ’25CHF 233.50
CHF 298.00
+27.6%
19.5%CHF 450.00CHF 225.00n/a18
Jan ’25CHF 244.50
CHF 307.11
+25.6%
19.6%CHF 472.00CHF 225.00n/a19
Dec ’24CHF 239.60
CHF 307.83
+28.5%
18.7%CHF 472.00CHF 225.00n/a18
Nov ’24CHF 237.70
CHF 307.83
+29.5%
18.7%CHF 472.00CHF 225.00n/a18
Oct ’24CHF 250.45
CHF 313.44
+25.2%
17.2%CHF 478.00CHF 250.00n/a18
Sep ’24CHF 259.45
CHF 321.12
+23.8%
16.6%CHF 477.27CHF 250.00n/a19
Aug ’24CHF 270.60
CHF 326.77
+20.8%
16.1%CHF 477.48CHF 250.00n/a20
Jul ’24CHF 273.50
CHF 328.02
+19.9%
16.0%CHF 456.47CHF 250.00CHF 250.1019
Jun ’24CHF 289.75
CHF 333.63
+15.1%
15.9%CHF 456.47CHF 250.00CHF 231.0021
May ’24CHF 280.35
CHF 335.49
+19.7%
15.3%CHF 450.00CHF 250.00CHF 220.6022
Apr ’24CHF 260.95
CHF 344.08
+31.9%
15.3%CHF 450.00CHF 250.00CHF 229.7023
Mar ’24CHF 271.10
CHF 349.87
+29.1%
13.9%CHF 450.00CHF 250.00CHF 233.2024
Feb ’24CHF 279.40
CHF 354.91
+27.0%
13.3%CHF 465.00CHF 265.00CHF 233.5024
Jan ’24CHF 290.50
CHF 371.08
+27.7%
11.0%CHF 450.00CHF 300.00CHF 244.5024
Dec ’23CHF 310.00
CHF 373.83
+20.6%
10.6%CHF 450.00CHF 300.00CHF 239.6024
Nov ’23CHF 329.50
CHF 375.29
+13.9%
10.5%CHF 450.00CHF 300.00CHF 237.7024
Oct ’23CHF 323.45
CHF 376.25
+16.3%
10.8%CHF 450.00CHF 300.00CHF 250.4524
Sep ’23CHF 312.80
CHF 374.13
+19.6%
9.5%CHF 444.00CHF 300.00CHF 259.4523
Aug ’23CHF 315.40
CHF 374.13
+18.6%
9.5%CHF 444.00CHF 300.00CHF 270.6023
Jul ’23CHF 320.40
CHF 386.26
+20.6%
10.0%CHF 475.80CHF 330.00CHF 273.5023

Analyst Forecast: Target price is less than 20% higher than the current share price.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Simply Wall St™
Simply Wall Street Pty Ltd
Level 7, 320 Pitt Street, Sydney
Download on the App StoreGet it on Google Play
Popular Markets
USAUUKINCAZA
About UsCareersPlansLogin
Help CenterLatest CoveragePodcastsAffiliate ProgramBusiness & Enterprise
Financial Services GuideTerms and ConditionsPrivacy PolicyLogos provided by Clearbit
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.